A clearer question.
A stronger scientific foundation.
Our planned research focus connects unmet clinical needs with carefully selected cell and gene therapy technologies.
BEGIN WITH THE QUESTION
Different approaches. A clear basis for decisions.
CELL THERAPY
Next-generation CAR-T
Evaluate technologies with initial evidence and transfer potential. Product selection connects patient needs, cell source, research evidence, manufacturability and rights.
- Starting point
- Target patients and treatment context
- Decision basis
- Reviewable data and an executable development path
DNA
Ex vivo editing: understand the product need
Editing can be part of a cell therapy product. Assessment considers intended changes, unintended effects, analytical capability and quality requirements. Technology and lead indication remain subject to specialist selection.